PeptideOS
← Library

MOTS-c

Mitochondrial-derived peptide

Also known as: Mitochondrial ORF of the 12S rRNA type-c

Tier 3, Preclinical only

Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.

Half-life
Not established

No validated pharmacokinetic half-life located in an allowed primary source. 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region.

Dosing
No established dose

No established human dose. Animal studies use body-weight-based intraperitoneal/subcutaneous dosing (mg/kg); not standardized. Kept qualitative per instructions.

Regulatory status
Not approved. Preclinical/experimental mitochondrial-derived peptide.
Evidence base
animal only · confidence: low

Rodent metabolic/exercise studies and mechanistic work; no controlled human efficacy or PK data in allowed sources.

Safety

No human safety data. Preclinical only; safety in humans unestablished. Not for clinical dosing decisions.